poisar

Stocks · News reference

Clinuvel Pharmaceuticals Files Marketing Authorisation Dossier for NEURACTHEL® Instant in Europe

Fiscal.ai

Clinuvel Pharmaceuticals has submitted a marketing authorisation dossier for its second pharmaceutical product, NEURACTHEL® Instant (tetracosactide), to European regulators via the decentralised procedure.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncClinuvel Pharmaceuticals Ltd

    A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

    CLINUVEL Pharmaceuticals announced its tenth consecutive annual profit for FY2026 with revenues of $94.0 million and net profit after tax of $33.9 million. The company declared a $0.05 per share dividend and increased cash reserves to $252.1 million, providing financial independence to pursue expansion strategy, particularly in North America. Despite marginal revenue decline due to U.S. market competition and inventory practice changes, the company maintained disciplined expense control and achieved record SCENESSE treatment volumes.